CETUXIMAB IN THE FIRST-LINE TREATMENT OF RAS WILD-TYPE METASTATIC COLORECTAL CANCER WITH LIVER-LIMITED DISEASE

被引：1
|
作者：
Souza, P., V [1 ]
Zanini, F. E. [1 ]
Biglia, L., V [1 ]
Kim, H. S. [2 ]
Fahham, L. [2 ]
机构：
[1] Merck, Sao Paulo, Brazil
[2] SENSE Co, Sao Paulo, Brazil
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.2578
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN26
引用
收藏
页码：A875 / A875
页数：1
相关论文
共 50 条
  • [31] Quality of life analysis in patients with RAS wild-type metastatic colorectal cancer treated with first-line FOLFIRI plus cetuximab in the CRYSTAL study
    Yamaguchi, K.
    Ando, M.
    Ooki, A.
    Beier, F.
    Guenther, S.
    Von Hohnhorst, P.
    Van Cutsem, E.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S370 - S371
  • [32] Treatment of Liver-Limited Metastatic Colorectal Cancer
    Hubbard, Joleen M.
    Alberts, Steven R.
    CANCER JOURNAL, 2010, 16 (03): : 235 - 240
  • [33] Therapeutic effect of biweekly cetuximab combined with first-line chemotherapy on KRAS/RAS wild-type advanced colorectal cancer
    Li, Jing
    Li, Jianjiong
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (10): : 12348 - 12355
  • [34] Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer
    Patel, Shiven B.
    Gill, David
    Garrido-Laguna, Ignacio
    ONCOTARGETS AND THERAPY, 2016, 9 : 75 - 86
  • [35] Role of cetuximab in first-line treatment of metastatic colorectal cancer
    Miguel Jhonatan Sotelo
    Beatriz García-Paredes
    Carlos Aguado
    Javier Sastre
    Eduardo Díaz-Rubio
    World Journal of Gastroenterology, 2014, (15) : 4208 - 4219
  • [36] Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer
    Laurent-Puig, Pierre
    Grisoni, Marie-Lise
    Heinemann, Volker
    Liebaert, Francois
    Neureiter, Daniel
    Jung, Andreas
    Montestruc, Francois
    Gaston-Mathe, Yann
    Thiebaut, Raphaeele
    Stintzing, Sebastian
    CLINICAL CANCER RESEARCH, 2019, 25 (01) : 134 - 141
  • [37] Role of cetuximab in first-line treatment of metastatic colorectal cancer
    Sotelo, Miguel Jhonatan
    Garcia-Paredes, Beatriz
    Aguado, Carlos
    Sastre, Javier
    Diaz-Rubio, Eduardo
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (15) : 4208 - 4219
  • [38] Cost-effectiveness of cetuximab plus FOLFIRI versus bevacizumab plus FOLFIRI in the first-line treatment of RAS wild-type metastatic colorectal cancer in China.
    Van Oostrum, Ilse
    Hu Yannan
    Yuan Zijiao
    Schlichting, Michael
    Tao Libo
    Pescott, Chris P.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [39] Comparative efficacy of cetuximab combined with FOLFOX or CAPEOX in first-line treatment of RAS/BRAF wild-type metastatic colorectal cancer: a multicenter case-control study
    Xu, Chang
    Ren, Jing
    Liu, Changqing
    Gai, Yi
    Cheng, Xiangyu
    Wang, Yusheng
    Wang, Guangyu
    ANTI-CANCER DRUGS, 2025, 36 (05) : 383 - 393
  • [40] First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study
    Liu, Shousheng
    Jiang, Chang
    Yang, Lin
    Huang, Jinsheng
    Peng, Roujun
    Wang, Xiaopai
    He, Wenzhuo
    Bai, Long
    Zhou, Yixin
    Zhang, Bei
    Xia, Liangping
    SCIENTIFIC REPORTS, 2020, 10 (01)
12345